Cantor Fitzgerald raised the firm’s price target on Xencor (XNCR) to $42 from $40 and keeps an Overweight rating on the shares. By this time next year, Cantor expects Xencor could have a recommended Phase 3 dose identified for two different T-cell engage antibodies, with Phase 3s both starting in 2027, as well as a Phase 2b UC study of long-acting TL1A antibody ‘942 largely or even fully enrolled, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor price target lowered to $18 from $20 at JPMorgan
- Xencor Reports Improved Q3 2025 Financial Results
- Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating
- Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating
- Xencor reports Q3 EPS (8c), consensus (70c)